OBSEVA SA |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.006 CHF | +36.36% |
|
+20.00% | -83.15% |
| 04-03 | ObsEva to Delist from the SIX Swiss Exchange | MT |
| 03-20 | ObsEva SA Announces to Wind-Down the Operations | CI |
| Sales 2021 | - | Sales 2022 | 19.64M 17.93M 26.84M | Capitalization | 18.07M 16.5M 24.7M |
|---|---|---|---|---|---|
| Net income 2021 | -58M -52.97M -79.28M | Net income 2022 | -29M -26.49M -39.64M | EV / Sales 2021 | - |
| Net cash position 2021 | 28.08M 25.64M 38.38M | Net cash position 2022 | 5.4M 4.93M 7.38M | EV / Sales 2022 | 0.65 x |
| P/E ratio 2021 |
-2.61
x | P/E ratio 2022 |
-0.45
x | Employees | 15 |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 70.16% |
More Fundamentals
* Assessed data
More news
| 1 day | +36.36% | ||
| 1 week | +20.00% | ||
| Current month | -53.85% | ||
| 1 month | -52.00% | ||
| 3 months | -87.63% | ||
| 6 months | -86.98% | ||
| Current year | -83.15% |
1 week
0.00
0.01
1 month
0.000.02
Current year
0.000.08
1 year
0.000.09
3 years
0.003.54
5 years
0.0015.00
10 years
0.0021.90
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 45 | 23-04-30 | |
Ernest Loumaye
FOU | Founder | 71 | 12-11-13 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Ernest Loumaye
FOU | Founder | 71 | 12-11-13 |
Luigi Marro
BRD | Director/Board Member | - | 23-06-28 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 0.0088 | +46.67% | 882,377 |
| 24-04-25 | 0.006 | +36.36% | 782,387 |
| 24-04-24 | 0.0044 | -18.52% | 688,100 |
| 24-04-23 | 0.0054 | +8.00% | 185,747 |
| 24-04-22 | 0.005 | 0.00% | 462,016 |
End-of-day quote Swiss Exchange, April 24, 2024
More quotes
Obseva SA is a Switzerland-based company active in the pharmaceutical and medical research sector. The Company develops oral compounds to treat womenâs reproductive health conditions from conception to birth. Its pipeline includes three product candidates: Linzagolix (OBE2109), an oral gonadotropin-releasing hormone (GnRH) receptor antagonist intended for the treatment of endometriosis and uterine fibroids; Nolasiban (OBE001), an oral oxytocin receptor antagonist, with the potential to inhibit uterine contractions at the time of embryo transfer, thereby enhancing embryo implantation during assisted reproductive technologies (ART), and OBE022, an oral and selective prostaglandin F2 alpha (PGF2a) receptor antagonist designed to control preterm labor.
Calendar
2024-05-14
- Q1 2024 Earnings Release (Projected)
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -83.15% | 1.13M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- OBSN Stock
